What is it about?
Melanoma cells resistant to BRAF inhibitors like dabrafenib adapt differently, with some maintaining high growth and others slowing down. HIV drugs doravirine and cabotegravir show promise in reactivating cell death and reducing cancer growth, offering a potential new therapy.
Featured Image
Photo by Bermix Studio on Unsplash
Why is it important?
This study tackles melanoma resistance to BRAF inhibitors, a key treatment challenge. By showing HIV drugs can curb resistant cells, it offers hope for new therapies to improve outcomes in aggressive melanoma cases.
Perspectives
This research suggests HIV drugs could complement or replace BRAF inhibitors in resistant melanoma, paving the way for innovative treatments. Future studies should confirm safety, refine dosing, and explore broader cancer applications.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells, International Journal of Molecular Sciences, November 2024, MDPI AG,
DOI: 10.3390/ijms252211939.
You can read the full text:
Contributors
The following have contributed to this page
